Research Nester Logo.jpg
Optic Neuritis Treatment Market revenue to hit USD 450 Million by 2035, says Research Nester
27. September 2023 07:00 ET | Research Nester
New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The global optic neuritis treatment market size is slated to expand at ~ 5% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD...
RND logo.PNG
Hematological Cancers Therapeutics Market to Reach $66.34 Billion By 2026 | Reports And Data
20. Februar 2019 05:07 ET | Reports And Data
High disease prevalence across the globe coupled with ongoing research and development is expected to stimulate market growth Market Size – USD 31.32 billion in 2018, Market Growth - CAGR of 9.8%,...
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS
21. März 2018 09:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, March 21, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been...
Cleartronic, Inc.
Cleartronic’s (CLRI) ReadyOp™ Software Platform Used in Clinical Trial
18. September 2017 13:00 ET | Cleartronic, Inc.
BOCA RATON, Fla., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cleartronic, Inc. (OTCPINK:CLRI) announced that its wholly owned subsidiary, ReadyOp Communications, Inc., played an important role in a...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
25. Mai 2017 07:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are...
Elite Pharmaceuticals, Inc. Logo
Elite Announces U.S. FDA Priority Review Designation for SequestOx™ NDA
17. März 2016 07:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
09. November 2015 16:37 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
22. April 2014 07:41 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 22, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
14. Februar 2014 09:49 ET | Elite Pharmaceuticals, Inc.
Revenues Increase by 154%, Product Development Accelerating Conference Call Scheduled for Tuesday, February 18 at 3:00 PM ET NORTHVALE, N.J., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Elite...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
14. Januar 2014 13:21 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in...